The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single ... X systems. Sequencing instruments revenue totaled $155 ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results , but sales were flat year on year at $1.1 billion. On the ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of ...

High-throughput technologies such as array-comparative genomic hybridization and next-generation sequencing provide unprecedented levels of information regarding individual tumors and can be ...

New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc.

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant ...